Bildkälla: Stockfoto

Alzecure: Approved for additional doses in ACD856 phase I study - Redeye

We give a brief comment on today's news from Alzecure's ACD856 Phase I study.

We give a brief comment on today's news from Alzecure's ACD856 Phase I study.
Börsvärldens nyhetsbrev
ANNONSER